Genomic Health's Revenues Rise 22 Percent; Slashes Loss

Though the number of the firm's OncoType DX tests delivered was basically flat from the fourth quarter of 2009, its year over year revenues were up 22 percent.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories